Showering c-MET-dependent cancers with drugs

Current Opinion in Genetics and Development

Volumn 18, Issue 1, 2008, Pages 87-96

  Knudsen, Beatrice S ^a   Vande Woude, George ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AM 102; AMG 102; ANTINEOPLASTIC AGENT; ARQ 197; AV 299; CGEN 241; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; JNJ 38877605; MGCD 265; MONOCLONAL ANTIBODY; MP 470; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR INHIBITOR; SGK 523; VASCULOTROPIN RECEPTOR; XL 184; XL 880;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; DRUG RESEARCH; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 43749091506     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.02.001     Document Type: Review

References (110)

1. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., and Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (1999) 60-70
2. Herbst R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30 (2003) 34-46
3. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 (2005) 1147-1157
4. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 (2002) 10-14
5. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
6. Rowinsky E.K., Youssoufian H., Tonra J.R., Solomon P., Burtrum D., and Ludwig D.L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13 (2007) 5549s-5555s
7. Zhu M.J., Ou W.B., Fletcher C.D., Cohen P.S., Demetri G.D., and Fletcher J.A. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene 26 (2007) 6386-6395
8. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. MET, metastasis, motility and more. Nat Rev Mol Cell Biol 4 (2003) 915-925. Comprehensive review of c-MET function in development and cancer.
9. Birchmeier C., and Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8 (1998) 404-410
10. Zhang Y.W., and Vande Woude G.F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88 (2003) 408-417
11. Stewart F. Roles of mesenchymal-epithelial interactions and hepatocyte growth factor-scatter factor (HGF-SF) in placental development. Rev Reprod 1 (1996) 144-148
12. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., and Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373 (1995) 702-705
13. Woolf A.S., Kolatsi-Joannou M., Hardman P., Andermarcher E., Moorby C., Fine L.G., Jat P.S., Noble M.D., and Gherardi E. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol 128 (1995) 171-184
14. Zachow R., and Uzumcu M. The hepatocyte growth factor system as a regulator of female and male gonadal function. J Endocrinol 195 (2007) 359-371
15. Chmielowiec J., Borowiak M., Morkel M., Stradal T., Munz B., Werner S., Wehland J., Birchmeier C., and Birchmeier W. c-Met is essential for wound healing in the skin. J Cell Biol 177 (2007) 151-162. In a conditional c-MET knockout, a few keratinocytes escape recombination and continue to express c-MET. Wound closure is delayed and when it occurs, only c-MET expressing keratinocytes close the wound.
16. Gherardi E., Sharpe M., Lane K., Sirulnik A., and Stoker M. Hepatocyte growth factor/scatter factor (HGF/SF), the c-MET receptor and the behaviour of epithelial cells. Symp Soc Exp Biol 47 (1993) 163-181
17. Huh C.G., Factor V.M., Sanchez A., Uchida K., Conner E.A., and Thorgeirsson S.S. Hepatocyte growth factor/c-MET signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 101 (2004) 4477-4482
18. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., and Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373 (1995) 699-702
19. Sachs M., Brohmann H., Zechner D., Muller T., Hulsken J., Walther I., Schaeper U., Birchmeier C., and Birchmeier W. Essential role of Gab1 for signaling by the c-MET receptor in vivo. J Cell Biol 150 (2000) 1375-1384
20. Birchmeier C., Birchmeier W., and Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 156 (1996) 217-226
21. Borowiak M., Garratt A.N., Wustefeld T., Strehle M., Trautwein C., and Birchmeier C. MET provides essential signals for liver regeneration. Proc Natl Acad Sci U S A 101 (2004) 10608-10613
22. Moumen A., Patane S., Porras A., Dono R., and Maina F. MET acts on Mdm2 via mTOR to signal cell survival during development. Development 134 (2007) 1443-1451
23. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., and Pan B.S. Lung cancer cell lines harboring MET gene amplification are dependent on MET for growth and survival. Cancer Res 67 (2007) 2081-2088
24. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., et al. Functional expression and mutations of c-MET and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65 (2005) 1479-1488
25. Shinomiya N., Gao C.F., Xie Q., Gustafson M., Waters D.J., Zhang Y.W., and Vande Woude G.F. RNA interference reveals that ligand-independent MET activity is required for tumor cell signaling and survival. Cancer Res 64 (2004) 7962-7970
26. Taulli R., Scuoppo C., Bersani F., Accornero P., Forni P.E., Miretti S., Grinza A., Allegra P., Schmitt-Ney M., Crepaldi T., et al. Validation of MET as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66 (2006) 4742-4749
27. Corso S., Comoglio P.M., and Giordano S. Cancer therapy: can the challenge be MET?. Trends Mol Med 11 (2005) 284-292
28. Gao C.F., and Vande Woude G.F. HGF/SF-MET signaling in tumor progression. Cell Res 15 (2005) 49-51
29. Kermorgant S., and Parker P.J. c-MET signalling: spatio-temporal decisions. Cell Cycle 4 (2005) 352-355
30. Linehan W.M., Pinto P.A., Srinivasan R., Merino M., Choyke P., Choyke L., Coleman J., Toro J., Glenn G., Vocke C., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13 (2007) 671s-679s
31. Peschard P., and Park M. From Tpr-MET to MET, tumorigenesis and tubes. Oncogene 26 (2007) 1276-1285
32. Hu B., Guo P., Bar-Joseph I., Imanishi Y., Jarzynka M.J., Bogler O., Mikkelsen T., Hirose T., Nishikawa R., and Cheng S.Y. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26 (2007) 5577-5586
33. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16 (1997) 68-73
34. Fischer J., Palmedo G., von Knobloch R., Bugert P., Prayer-Galetti T., Pagano F., and Kovacs G. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17 (1998) 733-739
35. Tsuda M., Davis I.J., Argani P., Shukla N., McGill G.G., Nagai M., Saito T., Lae M., Fisher D.E., and Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67 (2007) 919-929
36. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., Holcomb T., Pujara K., Stinson J., Fu L., et al. Somatic mutations lead to an oncogenic deletion of MET in lung cancer. Cancer Res 66 (2006) 283-289
37. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B., and Vande Woude G.F. A novel germ line juxtamembrane MET mutation in human gastric cancer. Oncogene 19 (2000) 4947-4953
38. Peschard P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y., and Park M. Mutation of the c-Cbl TKB domain binding site on the MET receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8 (2001) 995-1004
39. Jeffers M., Fiscella M., Webb C.P., Anver M., Koochekpour S., and Vande Woude G.F. The mutationally activated MET receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95 (1998) 14417-14422
40. Graveel C., Su Y., Koeman J., Wang L.M., Tessarollo L., Fiscella M., Birchmeier C., Swiatek P., Bronson R., and Vande Woude G. Activating MET mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101 (2004) 17198-17203
41. Berthou S., Aebersold D.M., Schmidt L.S., Stroka D., Heigl C., Streit B., Stalder D., Gruber G., Liang C., Howlett A.R., et al. The MET kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23 (2004) 5387-5393
42. Rong S., Bodescot M., Blair D., Dunn J., Nakamura T., Mizuno K., Park M., Chan A., Aaronson S., and Vande Woude G.F. Tumorigenicity of the MET proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12 (1992) 5152-5158
43. Jeffers M., Rong S., Anver M., and Vande Woude G.F. Autocrine hepatocyte growth factor/scatter factor-MET signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene 13 (1996) 853-856
44. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., Resau J.H., and Vande Woude G.F. MET and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57 (1997) 5391-5398
45. Rong S., Jeffers M., Resau J.H., Tsarfaty I., Oskarsson M., and Vande Woude G.F. MET expression and sarcoma tumorigenicity. Cancer Res 53 (1993) 5355-5360
46. Bardelli A., Maina F., Gout I., Fry M.J., Waterfield M.D., Comoglio P.M., and Ponzetto C. Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Oncogene 7 (1992) 1973-1978
47. Faletto D.L., Kaplan D.R., Halverson D.O., Rosen E.M., and Vande Woude G.F. Signal transduction in c-MET mediated motogenesis. EXS 65 (1993) 107-130
48. Webb C.P., Taylor G.A., Jeffers M., Fiscella M., Oskarsson M., Resau J.H., and Vande Woude G.F. Evidence for a role of MET-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17 (1998) 2019-2025
49. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
50. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
51. Tamagnone L., Artigiani S., Chen H., He Z., Ming G.I., Song H., Chedotal A., Winberg M.L., Goodman C.S., Poo M., et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99 (1999) 71-80
52. Birchmeier W., Weidner K.M., and Behrens J. Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. J Cell Sci Suppl 17 (1993) 159-164
53. Birchmeier W., Brinkmann V., Niemann C., Meiners S., DiCesare S., Naundorf H., and Sachs M. Role of HGF/SF and c-MET in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 212 (1997) 230-240 discussion 240-236
54. Rodrigues G.A., Park M., and Schlessinger J. Activation of the JNK pathway is essential for transformation by the MET oncogene. EMBO J 16 (1997) 2634-2645
55. Royal I., and Park M. Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J Biol Chem 270 (1995) 27780-27787
56. Turner F.E., Broad S., Khanim F.L., Jeanes A., Talma S., Hughes S., Tselepis C., and Hotchin N.A. Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes. J Biol Chem 281 (2006) 21321-21331
57. Mejlvang J., Kriajevska M., Vandewalle C., Chernova T., Sayan A.E., Berx G., Mellon J.K., and Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 18 (2007) 4615-4624
58. Guo A., Villen J., Kornhauser J., Lee K.A., Stokes M.P., Rikova K., Possemato A., Nardone J., Innocenti G., Wetzel R., et al. Signaling networks assembled by oncogenic EGFR and c-MET. Proc Natl Acad Sci U S A 105 (2008) 692-697. Identification of a core network of ∼50 phospho-proteins and pathways that are responsive to drug inhibition.
59. Basile J.R., Barac A., Zhu T., Guan K.L., and Gutkind J.S. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res 64 (2004) 5212-5224
60. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., Tamagnone L., and Comoglio P.M. The semaphorin 4D receptor controls invasive growth by coupling with MET. Nat Cell Biol 4 (2002) 720-724
61. Sulpice E., Plouet J., Berge M., Allanic D., Tobelem G., and Merkulova-Rainon T. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 111 (2007) 2036-2045
62. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043. c-MET amplification and activation causes drug resistance by phosphorylating and activating ErbB3 signaling.
63. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290. Multiple receptor tyrosine kinases, including c-MET, EGFR, PDGFR, c-kit, signal to Gab-1 and all have to be inhibited to kill cancer cells.
64. Anderson A.R., Weaver A.M., Cummings P.T., and Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127 (2006) 905-915
65. Smallbone K., Gatenby R.A., Gillies R.J., Maini P.K., and Gavaghan D.J. Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol 244 (2007) 703-713
66. Gillies R.J., and Gatenby R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26 (2007) 311-317
67. Gao C., Furge K., Koeman J., Dykema K., Su Y., Cutler M.L., Werts A., Haak P., and Vande Woude G.F. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A 104 (2007) 8995-9000. Chromosome instability and changes in chromosome content occur with phenotypic switching and generate the necessary chromosome diversity in the tumor cell populations to allow for environment-facilitated expansion and evolution of tumor cell populations.
68. Gao C.F., Xie Q., Su Y.L., Koeman J., Khoo S.K., Gustafson M., Knudsen B.S., Hay R., Shinomiya N., and Vande Woude G.F. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 102 (2005) 10528-10533. Isolation and molecular characterization of highly proliferative tumor cells and their revertants from highly invasive tumor cell populations, demonstrating that phenotypic shifting can contribute to malignant progression.
69. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26 (2007) 319-331. Description of molecular mechanisms of hypoxia-mediated cancer development and progression to metastasis.
70. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., Saito Y., Johnson R.S., Kretzler M., Cohen C.D., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117 (2007) 3810-3820
71. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., Koga Y., and Miyazaki K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-MET pathway. Int J Cancer 119 (2006) 2750-2759
72. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., and Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene. Cancer Cell 3 (2003) 347-361
73. Zhang Y.W., Su Y., Volpert O.V., and Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100 (2003) 12718-12723
74. Abounader R., and Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7 (2005) 436-451
75. Xin X., Yang S., Ingle G., Zlot C., Rangell L., Kowalski J., Schwall R., Ferrara N., and Gerritsen M.E. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158 (2001) 1111-1120
76. Desiderio M.A. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol Life Sci 64 (2007) 1341-1354
77. Kataoka H., Miyata S., Uchinokura S., and Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22 (2003) 223-236
78. Qiu D., Owen K., Gray K., Bass R., and Ellis V. Roles and regulation of membrane-associated serine proteases. Biochem Soc Trans 35 (2007) 583-587
79. Vande Woude G.F., Jeffers M., Cortner J., Alvord G., Tsarfaty I., and Resau J. MET-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 212 (1997) 119-130 discussion 130-112, 148-154
80. Abounader R., Ranganathan S., Kim B.Y., Nichols C., and Laterra J. Signaling pathways in the induction of c-MET receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem 76 (2001) 1497-1508
81. Gotte M., Kersting C., Radke I., Kiesel L., and Wulfing P. An expression signature of syndecan-1 (CD138), E-cadherin and c-MET is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 9 (2007) R8
82. Morgan T.M., Lange P.H., and Vessella R.L. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12 (2007) 3000-3009. The review paper describes how cancer cells can be isolated from bone marrow aspirates and characterized. The relationship between these cells and tumor metastasis is discussed on the basis of data from a large cohort of patients with prostate cancer.
83. Townson J.L., and Chambers A.F. Dormancy of solitary metastatic cells. Cell Cycle 5 (2006) 1744-1750. The review paper describes how cancer cells can be isolated from bone marrow aspirates and characterized. Conclusions about the relationship between these cells and tumor metastasis is discussed on the basis of data from a large cohort of patients with prostate cancer.
84. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., and Groom A.C. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153 (1998) 865-873
85. Mazzone M., and Comoglio P.M. The MET pathway: master switch and drug target in cancer progression. FASEB J 20 (2006) 1611-1621
86. Yaziji H., Goldstein L.C., Barry T.S., Werling R., Hwang H., Ellis G.K., Gralow J.R., Livingston R.B., and Gown A.M. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
87. Kim K.J., Wang L., Su Y.C., Gillespie G.Y., Salhotra A., Lal B., and Laterra J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12 (2006) 1292-1298
88. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., and Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 98 (2001) 7443-7448
89. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., Archibald H., Raudales R., Tam A., Lee D., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 104 (2007) 19936-19941
90. Nakamura Y., Matsubara D., Goto A., Ota S., Sachiko O., Ishikawa S., Aburatani H., Miyazawa K., Fukayama M., and Niki T. Constitutive activation of c-MET is correlated with c-MET overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci 99 (2008) 14-22
91. Christensen J.G., Burrows J., and Salgia R. c-MET as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225 (2005) 1-26. Comprehensive review of small molecules of c-MET kinase inhibitors, molecular characteristics of c-MET targets and rationale for the treatment strategies.
92. Littman B, Thompson J, Webb CP: Where are we heading/what do we really need? In Biomarkers in Drug Development: A Handbook of Practice, Application and Strategy. Edited by Bleavins M, Rahbari R, Jurima-Romet M, Carini C; 2008, in press.
93. Zhang Y.W., Graveel C., Shinomiya N., and Vande Woude G.F. MET decoys: will cancer take the bait?. Cancer Cell 6 (2004) 5-6
94. Burgess T., Coxon A., Meyer S., Sun J., Rex K., Tsuruda T., Chen Q., Ho S.Y., Li L., Kaufman S., et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-MET-dependent human tumors. Cancer Res 66 (2006) 1721-1729
95. Gordon M.S., Mendelson D.S., Sweeney C., Erbeck N., Patel R., Kakkar T., Yan L., Eckhardt S.G., and Gore L. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-MET receptor, in patients (pts) with advanced solid tumors. ASCO Annual Meeting. Chicago, IL (2007) 3551
96. Martens T., Schmidt N.O., Eckerich C., Fillbrandt R., Merchant M., Schwall R., Westphal M., and Lamszus K. A novel one-armed anti-c-MET antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12 (2006) 6144-6152
97. Matsumoto K., and Nakamura T. Hepatocyte growth factor and the MET system as a mediator of tumor-stromal interactions. Int J Cancer 119 (2006) 477-483
98. Peruzzi B., and Bottaro D.P. Targeting the c-MET signaling pathway in cancer. Clin Cancer Res 12 (2006) 3657-3660
99. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., and Salgia R. Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13 (2002) 41-59
100. Eder J.P., Heath E., Appleman L., Shapiro G., Wang D., Malburg L., Zhu A.-X., Leader T., Wolanski A., and LoRusso P. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. ASCO Annual Meeting. Chicago, IL (2007) 3526
101. Ross R.W., Stein M., Sarantopoulos J., Eisenberg P., Logan T., Srinivas S., Rosenberg J., and Vaishampayan U. A phase II study of the c-MET RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). ASCO Annual Meeting. Chicago, IL (2007) 15601
102. Zhang Y., Kaplan-Lefko P.J., Rex K., Yang Y., Moriguchi J., Osgood T., Mattson B., Coxon A., Burgess T.L., and Dussault I. Identification and characterization of a novel RON/c-MET small molecule inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA (2007) A223
103. Gessert S.F., Aubol B.E., Do T.H., Hendle J., Lee P.S., Jessen K.A., Froning K.J., Felce J.D., Sauder J.M., Schwinn K.D., et al. Selective inhibition of MET protein receptor tyrosine kinase by SGX53. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA (2007) C198
104. Rosen L., Senzer N., Nemunaitis J., Mekhail T., Bukowski R., Li C., Rulewski N., Dovholuk A., Chai F., and Chan T. A phase dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-MET inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA (2007) B91
105. Garcia A., Rosen L., Cunningham C.C., Nemunaitis J., Li C., Rulewski N., Dovholuk A., Savage R., Chan T., Bukowksi R., et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-MET RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. ASCO Annual Meeting. Chicago, IL (2007) 3525
106. Ma P.C., Jiang S., Du R., Dietrich S., Tang Z., and Kern J.A. Modeling targeted inhibition of wild type and mutated c-MET receptor. ASCO Annual Meeting. Chicago, IL (2007) 14010
107. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 (2004) 5355-5362
108. Rong S., Donehower L.A., Hansen M.F., Strong L., Tainsky M., Jeffers M., Resau J.H., Hudson E., Tsarfaty I., and Vande Woude G.F. MET proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55 (1995) 1963-1970
109. Jeffers M., Rong S., and Vande Woude G.F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16 (1996) 1115-1125
110. Zhang Y.W., Su Y., Lanning N., Gustafson M., Shinomiya N., Zhao P., Cao B., Tsarfaty G., Wang L.M., Hay R., et al. Enhanced growth of human MET-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24 (2005) 101-106